Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a 95 billion ...

Daiichi Sankyo aims to transform its antibody-drug conjugate (ADC) leadership into a top global oncology standing. | Daiichi ...

The Japanese drugmaker aims to more than double oncology revenue to above ¥2.3 trillion by 2030 and become one of the world's ...

Earlier this month, Daiichi Sankyo’s board met and revised its full-year consolidated forecast for the year ending March 31, ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Daiichi Sankyo unveils new five-year business plan focused on oncology leadership and innovation: Tokyo Tuesday, May 12, 2026, 11:00 Hrs [IST] Daiichi Sankyo revealed its next Fiv ...

While Enhertu has been delivering for Daiichi Sankyo and AZ commercially, there was a delay to the rollout of Datroway in a ...

"Eddie” Viriyahboubpha: Since the launch of your new cancer treatment in your fiscal year 2019, Daiichi Sankyo’s global ...

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, faces no material risk from its Japanese partner Daiichi Sankyo's decision to delay its full-year 2025 results, according to ...

The platform will be applied to identify potential biomarkers linked to treatment response prior to upcoming trial phases.

Why Daiichi Sankyo Company (TSE:4568) is on investors’ radar today Daiichi Sankyo Company (TSE:4568) has attracted attention after recent share moves, with a 1.4% gain over the past day and a 5.0% ...

TOKYO (Reuters) -Drugmaker Merck will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22 billion to the Japanese ...